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ABSTRACT 
Quantifying Parkinson’s Disease Symptoms Using Mobile Devices 
Charles Aylward 
Current assessments for evaluating the progression of Parkinson’s Disease are largely 
qualitative and based on small sets of data obtained from occasional doctor-patient interactions. 
There is a clinical need to improve the techniques used for mitigating common Parkinson’s 
Disease symptoms. Available data sets for researching the disease are minimal, hindering 
advancement toward understanding the underlying causes and effectiveness of treatment and 
therapies. Mobile devices present an opportunity to continuously monitor Parkinson’s Disease 
patients and collect important information regarding the severity of symptoms. The evolution of 
digital technology has opened doors for clinical research to extend beyond the clinic by 
incorporating complex sensors in commonly used devices. Leveraging these sensors to quantify 
characteristic Parkinson’s Disease symptoms may drastically improve patient care and the 
reliability of symptom assessment.  
                The goal of this project is to design and develop a system for measuring and analyzing 
the cardinal symptoms of Parkinson’s using mobile devices. An application for the iPhone and 
Apple Watch is developed, utilizing the sensors on the devices to collect data during the 
performance of motor tasks. Assessments for tremor, bradykinesia, and postural instability are 
implemented to mimic UPDRS evaluations normally performed by a neurologist. The application 
connects to a cloud-based server to transfer the collected data for remote access and analysis. 
Example MatLab analysis demonstrates potential approaches for extracting meaningful data to be 
used for monitoring the progression of Parkinson’s Disease and the effectiveness of treatment and 
therapies. High-level verification testing is performed to show general efficacy of the assessment 
tasks. The system design successfully lays the groundwork for a mobile device-based assessment 
tool to objectively measure Parkinson’s Disease symptoms.  
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CHAPTER 1 
 
BACKGROUND 
1.1 INTRODUCTION 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the 
manifestation of motor and non-motor dysfunction [1]. While research has shown the disease 
results from a complicated interplay of genetic and environmental factors, the cause of the disease 
remains unknown [2]. Further complexity arises from clinical challenges with the disease, 
including difficulty in making a definitive diagnosis at the early stages and management of 
symptoms at later stages [2]. The disease is assessed based on clinical criteria with no universally 
established test dictating proper evaluation [1]. A number of rating scales are used to measure 
motor impairment, but most of them have not been fully evaluated for validity and reliability [1]. 
Current treatments reduce symptoms but do not slow the neurodegenerative behavior of the 
disease.  
1.2 HISTORY 
In 1817, James Parkinson published “An Essay on the Shaking Palsy” in which he 
describes six cases of people with a condition Parkinson called paralysis agitans, or shaking 
palsy. He details the progression of disability characterized by increasing tremor severity, 
deteriorating muscle strength, and hunched over posture in his publication: 
Involuntary tremulous motion, with lessened muscular power, in parts not in action and 
even when supported; with a propensity to bend the trunk forward, and to pass from a 
walking to a running pace: the senses and intellects being uninjured.1  
																																																													
1 James Parkinson, An Essay on the Shaking Palsy 
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Parkinson notably distinguishes the tremor symptoms he observed from tremors experienced in 
cases of epilepsy, alcoholism, or stroke. He observed gradual onset of the symptoms with motor 
impairment beginning in the limbs before moving to the rest of the body. Parkinson concluded 
from the symptoms he observed that paralysis agitans, as he labelled the syndrome, resulted from 
lesions in the cervical spinal cord but failed to find evidence in post-mortem studies. Four 
decades later, French doctor Jean-Martin Charcot, known as “the father of clinical neurology”, 
added symptoms to the syndrome and labelled it Parkinson’s Disease to honor the work of James 
Parkinson. 
1.3 CARDINAL FEATURES 
There are four cardinal features of PD often described using the abbreviation TRAP: 
tremor, rigidity, akinesia (or bradykinesia), and postural instability [3]. Motor symptoms usually 
begin gradually and worsen over time, creating difficulties in walking, talking, and other simple 
tasks.  While motor symptoms are often used to gauge the severity of the disease, non-motor 
symptoms are also impacted. Non-motor symptoms may include mental and behavioral changes, 
sleep problems, depression, memory loss, and fatigue [4].  
1.3.1 Causes of PD 
 A combination of environmental and genetic factors is believed to cause the 
neurodegeneration associated with PD [20]. Scientists have identified several genetic mutations 
linked to PD, most notably the alpha-synuclein gene [4]. While researchers recognize genetic 
factors are closely tied to PD, most believe environmental exposures increase a person’s risk of 
developing the disease [4]. The same genes and proteins that are altered in inherited cases may 
also be altered in sporadic cases resulting from toxins or other factors [4]. PD symptoms begin to 
arise following the gradual death of nerve cells in a small portion of the lower brain called the 
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substantia nigra [11]. These cells normally connect to the striatum in the brain’s basal ganglia 
under the cerebral cortex and release the neurotransmitter dopamine to produce smooth, 
purposeful movement [4, 11]. Insufficient dopamine in this circuit results in abnormal nerve-
firing patterns causing impaired movement [4]. The cardinal motor impairments associated with 
PD manifest when roughly 80% of dopamine has been depleted from the basal ganglia [3, 11].  
1.3.2 Tremor 
 Tremor, or shaking, is often the first symptom of affected patients and is the most 
common and easily recognizable among those impacted by the disease. Tremor usually begins in 
the arm or hand and progresses to other parts of the body, though not typically to the same extent 
as the initial location [5]. In some cases, tremor may only affect one side of the body and may 
also affect the chin, tongue, and lips [5]. Tremor motor symptoms are not unique to Parkinson’s 
Disease. Another condition often confused with Parkinsonian tremor is Essential Tremor, which 
induces similar dysfunction but subtle differences make it distinguishable from PD. Essential 
Tremor symptoms increase with motion and are more symmetric than seen in PD patients [21]. 
Essential Tremor patients do not respond to PD medications making it clear the symptoms do not 
share a root cause [21]. Parkinsonian tremor has an oscillation frequency of 4-6Hz at the distal 
end of the affected limb and occurs with a supination-pronation motion, also referred to as “pill 
rolling” [1]. Parkinsonian tremor is most present at rest and usually decreases with motion, 
mental concentration, and during sleep [1]. Some PD patients have also reported an “internal” 
shaking not associated with visible tremor [1]. PD patients may also experience a postural tremor, 
known as “re-emergent tremor”, identified by outstretching the arms in a horizontal plane [3]. 
The term “re-emergent” refers to the delay of one to several seconds for the tremor to occur after 
extending the arms [42]. Postural tremor and resting tremor occur at the same frequency and are 
reduced by the same therapy, indicating a shared root cause. PD patients may also experience 
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tremor during voluntary movement, known as kinetic tremor, which is often assessed during a 
writing task or finger-to-nose motion [42]. Tremors symptoms are not present among all PD 
patients and severity fluctuates as the disease progresses [1].   
1.3.3 Rigidity 
 Rigidity associated with PD is characterized by uniform resistance to movement present 
in both agonist and antagonist muscles recruited for the movement [3]. Increased stiffness can 
affect the neck, shoulders, hips, trunk, ankles and wrists [3]. Normal muscle control involves a 
relaxed state at rest, and a flexed state when moved. In Parkinsonian rigidity, the affected muscles 
are constantly flexed, often leading to a decreased range of motion [3]. The presence of rigidity is 
commonly identified while the affected person is walking with little to no swing of the arms [6].  
A neurologist often identifies the symptom by moving the patient’s arm and observing a ratchet-
like motion with short, jerky movement referred to as the “cogwheel phenomenon” [3]. Pain is 
often associated with rigidity in PD patients, commonly misdiagnosed as other forms of 
rheumatology or skeletomuscular injury [3].  Postural deformities may arise from rigidity 
symptoms among PD patients [3]. Some cases of axial postures (i.e. scoliosis or anterocollis) 
have manifested through rigidity in the neck and trunk late in the disease [3].  
1.3.4 Akinesia and Bradykinesia 
 Often considered the most debilitating symptom of PD is a general lack or slowness of 
voluntary movement [23]. Akinesia specifically refers to a slowness or inability in the initiation 
of movement while bradykinesia refers to a slowness in the execution of movement [23]. 
Bradykinesia is the most characteristic motor symptom of Parkinson’s Disease and encompasses 
difficulties in planning, initiating, and executing movement [1]. Bradykinesia causes difficulty in 
performing repetitive movements, such as finger tapping, and simultaneous movement [4]. An 
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inability to perform simple tasks due to bradykinesia creates frustration among PD patients as 
activities once performed quickly and easily, such as getting dressed or washing the dishes, may 
take several hours [4]. bradykinesia may cause other discomforts including impaired swallowing, 
impaired speech, loss of facial expression, and decreased blinking [3]. With its many secondary 
symptoms, bradykinesia is often regarded as the most debilitating of the PD symptoms [3]. 
Assessment of bradykinesia symptoms usually involves observing cadence and amplitude while 
the patient performs rapid, repetitive, alternating movements such as finger tapping, heel tapping, 
hand gripping, and hand pronation-supination [1].  
1.3.5 Postural Instability 
Toward the late stages of the disease, following the onset of other clinical features, 
patients begin to experience postural instability and a loss of postural reflexes [3]. Postural 
instability refers to an instability while standing upright and a loss of reflexes to maintain an 
upright posture, often leading to balance issues [6]. The primary danger PD patients face due to 
postural instability is retropulsion, or a tendency to fall backward, leading to a predisposition to 
hip fractures [6]. Doctors test this using a “pull test”, in which the patient is pulled backward 
from the shoulders and their recovery is observed [6]. A normal recovery involves a quick step 
backwards to prevent falling, while those affected by postural instability would tumble backwards 
without assistance from the doctor [6].  
1.3.6 Non-motor Symptoms 
 The onset of non-motor symptoms may identify PD in some patients. Autonomic 
dysfunction, while more typically associated with other neurological disorders, affects many PD 
patients [1]. Examples include orthostatic hypotension, sweating dysfunction, sphincter 
dysfunction and erectile dysfunction [1]. PD patients may also experience cognitive and 
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neurobehavioral abnormalities with an increased risk for dementia, depression, apathy, anxiety, 
and hallucinations [1]. Other non-motor symptoms include sensory abnormalities and sleep 
disorders [1]. Measurement of non-motor symptoms provides insight on disease severity and is an 
ongoing research area for PD evaluation [22]. 
1.4 EVALUATION 
Several assessments are used to evaluate the symptoms and severity of Parkinson’s 
Disease with ranging focuses reflecting functional fluctuations and general level of function [3].  
The need for a metric to assess the effectiveness of therapeutic intervention was a driving force 
for creating rating scales [3]. As the disease progresses during treatment, evaluations can 
determine whether or not the treatment is effective. Often during the course of treatment, patients 
experience what doctors refer to as an ON/OFF phenomenon. Patients are considered ON when 
medication is working and OFF when the benefit subsides [3]. The patient’s ability to perform 
tasks can change dramatically between states, so far as being able to run across the room versus 
an inability to rise from a chair [3].  The following sections detail evaluation techniques used. 
1.4.1 Hoehn and Yahr 
 In 1967, Melvin Yahr and Margaret Hoehn published a system for evaluating the 
progression of Parkinson’s Disease in the journal Neurology [8]. The Hoehn and Yahr (HY) 
system utilizes 5 stages to describe and classify the severity of motor symptoms [8]. The system 
has since been modified to include steps 1.5 and 2.5 to account for intermediate stages [8]. The 
HY scale provides a simple method to categorize the severity of the disease to reflect the degree 
of progression [8]. However, the scale is not linear, and the ranking of stages does not always 
reflect progression as expected; in some cases, patients have more difficulty performing the stage 
2 assessment tasks than those in stage 3 [8]. The advantages of this scale are its popularity and 
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simplicity to carry out. However, the categorical scale and inaccurate rank-progression 
correlation has led the scale to be largely supplanted by the Unified Parkinson’s Disease Rating 
Scale [8]. The HY scale is shown in Table 1. 
Table 1. Modified Hoehn and Yahr scale [8] 
1.0 Unilateral involvement only 
1.5 Unilateral and axial involvement 
2.0 Bilateral involvement without impairment of balance 
2.5 Mild bilateral disease with recover on pull test 
3.0  Mild to moderate bilateral disease; some postural instability, physically independent 
4.0 Severe disability; still able to walk or stand unassisted 
5.0 Wheelchair bound or bedridden unless aided 
1.4.2 Schwab and England Activities of Daily Living 
 Developed by R. S. Schwab and A. C. England Jr., the Schwab and England activities of 
daily living (ADL) rating scale is frequently used to provide an estimate of severity based on the 
patient’s ability to perform common tasks [7]. The examination involves an interview with the 
patient and often includes a collateral source, such as a spouse [7]. The examiner will ask about 
the patient’s ability to perform common household chores and whether assistance is needed. The 
scale uses percentages to rank severity with 5% increments between 0%-100% [7]. Table 2 shows 
the sections of the Schwab and England ADL assessment. 
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Table 2. Schwab and England ADL scale [7] 
100% 
 
Completely independent. Able to do all chores without slowness, difficulty or impairment. 
Essentially normal. Unaware of any difficulty. 
90% Completely independent. Able to do all chores with some degree of slowness, difficulty and 
impairment. Might take twice as long. Beginning to be aware of difficulty. 
80% Completely independent in most chores. Takes twice as long. Conscious of difficulty and 
slowness 
70% Not completely independent. More difficulty with some chores. Three to four times as long in 
some. Must spend a large part of the day with chores. 
60% Some dependency. Can do most chores, but exceedingly slowly and with much effort. Errors; 
some impossible. 
50% More dependent. Help with half, slower, etc. Difficulty with everything. 
40% Very dependent. Can assist with all chores, but few alone. 
30% With effort, now and then does a few chores alone or begins alone. Much help needed 
20% Nothing alone. Can be a slight help with some chores. Severe invalid. 
10% Totally dependent, helpless. Complete invalid. 
0% Vegetative functions such as swallowing, bladder and bowel functions are not functioning. 
Bedridden. 
 
1.4.3 Unified Parkinson’s Disease Rating Scale (UPDRS) 
 The global “gold standard” rating scale for PD assessment is the Unified 
Parkinson’s Disease Rating Scale (UPDRS), owned and licensed by the International Parkinson 
and Movement Disorder Society [7]. The UPDRS was developed in an effort to incorporate 
elements from existing scales into a single comprehensive assessment [24]. However, the UPDRS 
has important limitations and has undergone several revisions since its development [7].  
In 1987, the official UPDRS was published by Stanley Fahn and the UPDRS Development 
Committee. The UPDRS includes four subscales covering behavioral features, activities of daily 
living, motor symptom ratings, and therapeutic complications [7]. Part I of the UPDRS covers 
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mentation, behavior, and mood and examines for intellectual impairments, thought disorders, 
depression, and changes in motivation [25]. Part II includes a 13 items that directly relate to daily 
activities such as dressing and eating while also examining patient perceptions of primary disease 
manifestations like tremor and salivation [24, 25]. Part III evaluates motor impairment including 
speech, facial expression, rest and postural tremor, rigidity, bradykinesia, posture, gait, and 
postural stability [25].  
In 2001, the International Movement Disorder Society (MDS) created a UPDRS task 
force with three main objectives: critique existing scales, identify clinical areas that are not 
adequately rated, and make recommendations on maintaining or modifying currently available 
scales [24]. The task force unanimously considered the concept of a single clinical rating scale to 
be an important tool for clear and consistent communication among movement disorder 
colleagues [24]. In 2003, the conclusions of the task force were published. They agreed the 
UPDRS has many strengths and provides an effective comprehensive assessment of motor 
symptoms associated with PD [24]. However, the weaknesses were substantial in the assessment 
of non-motor symptoms, leading the task force to develop a list of recommended improvements 
[25]. In 2008, based on the recommendations laid out by the task force, the MDS published an 
MDS-sponsored revision of the UPDRS (MDS-UPDRS) [26]. The four component design was 
retained with a shifted focus for each of the sections [26]. Part I of the MDS-UPDRS concerns 
“non-motor experiences of daily living”, Part II concerns “motor experiences of daily living”, 
Part III remains focused on motor symptom examination, and Part IV concerns “motor 
complications” [26]. In practice, the UPDRS test is combined with the HY and the Schwan and 
England ADL assessments [27]. Details for each part of the MDS-UPDRS assessment are shown 
in Table 3. 
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Table 3. MDS-UPDRS sections [26] 
Part I: Nonmotor Aspects of Experiences of Daily Living  
1.1 Cognitive impairment  
1.2 Hallucinations and psychosis  
1.3 Depressed mood  
1.4 Anxious mood 
1.5 Apathy Features of dopamine dysregulation syndrome 
1.6 Sleep problems  
1.7 Daytime sleepiness  
1.8 Pain and other sensations  
1.9 Urinary problems 
1.10 Constipation problems 
1.11 Lightheadedness on standing  
1.12 Fatigue  
Part II: Motor Experiences of Daily Living 
2.1 Speech 
2.2 Saliva and drooling 
2.3 Chewing and swallowing 
2.4 Eating tasks 
2.5 Dressing 
2.6 Hygiene 
2.7 Handwriting 
2.8 Doing hobbies and other activities 
2.9 Turning in bed 
2.10 Tremor impact on activities 
2.11 Getting in and out of bed 
2.12 Walking and balance 
2.13 Freezing 
Part III: Motor Examination 
3.1 Speech 
3.2 Facial expression 
3.3 Rigidity 
3.4 Finger tapping 
3.5 Hand movements 
3.6 Pronation–supination movements of hands 
3.7 Toe tapping 
3.8 Leg agility 
3.9 Arising from chair 
3.10 Gait 
3.11 Freezing of gait 
3.12 Postural stability 
3.13 Posture 
3.14 Global spontaneity of movement (body bradykinesia) 
3.15 Postural tremor of hands 
3.16 Kinetic tremor of hands 
3.17 Rest tremor amplitude 
3.18 Constancy of rest tremor 
Part IV: Motor Complications 
4.1 Dyskinesias: time spent with dyskinesias 
4.2 Dyskinesias: functional impact of dyskinesias 
4.3 Dyskinesias: painful off state dystonia 
4.4 Motor fluctuations: time spent in the off state 
4.5 Motor fluctuations: functional impact of fluctuations 
4.6 Motor fluctuations: complexity of motor fluctuations 
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1.5 PATIENT POPULATION 
 Parkinson’s Disease is one of the most common neurological disorders with an estimated 
one in every 1,000 people affected by the condition [10]. A widely accepted figure for the 
approximate prevalence of PD globally is 200 for every 100,000 individuals [10]. In the U.S., an 
estimated 750,000 to 1.5 million individuals are affected [10]. In the U.K., there are 120,000 to 
130,000 diagnosed individuals, but many more are affected that remain undiagnosed [10]. Men 
are 1.5 times more likely to than women to develop the condition and symptoms generally surface 
at age 60 [10]. The risk increases to one in 100 for those aged between 60 and 80 years of age, 
and one in 50 at age 80 [9]. There have been cases of the disorder in individuals under the age of 
20, known as juvenile parkinsonism [9].  While the disease prevalence is skewed toward later 
ages and occurs more frequently in men, there is no boundary in age, race, or gender [9]. A study 
by Hoehn and Yahr in 1967 observed mortality rates related to the condition. They found 61% of 
patients were dead or severely disabled 5-9 years after diagnosis, increasing to 80% after 10 years 
[10]. This rate has since been reduced with the advent of treatments such as Levodopa, a mainstay 
pharmacological treatment to supplement the loss of dopamine with PD, making it possible for 
PD patients to live out a normal length life [10, 11]. 
1.6 TREATMENTS 
 There is currently no cure for PD, but symptoms can be relieved with surgeries or 
medication [28]. The primary objective of medical management is to maximize control over the 
target signs and symptoms by selecting the appropriate drug, dosage, and frequency [25]. 
Symptoms and response to medication are highly variable from patient to patient and require a 
very individualized approach [25]. Drug therapies target motor symptoms by increasing 
dopamine levels in the brain or targeting neurotransmitters in the body and non-motor therapies 
focus on symptoms like depression [28]. The mainstay drug is levodopa (L-dopa) which provides 
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a dopamine precursor to nerve cells helping to replenish the brain’s reduced supply of dopamine 
[23]. Patients cannot simply take a dopamine pill because dopamine does not easily pass through 
the blood-brain barrier, a protective lining of cells inside blood vessels that regulate the transport 
of nutrients and substances in the brain [23]. Levodopa has a high rate of success with reducing or 
eliminating motor symptoms during the early stages of PD, allowing a majority of patients to 
extend the period in which they can lead active, productive lives [23].   
 When drug therapies are no longer sufficient, surgical approaches are used to relieve 
symptoms [23]. The earliest types of surgical techniques involved selectively destroying specific 
parts of the brain that contribute to symptoms [23]. These risky techniques have been largely 
replaced by deep brain stimulation (DBS), a technique in which an electrode is implanted into 
part of the brain and connected to a pulse generator implanted in the chest area [23]. When turned 
on, the pulse generator and electrode stimulate the brain painlessly to block signals that cause 
many of the motor symptoms of PD [23]. DBS is generally appropriate for patients who have 
levodopa-responsive PD and do not have memory problems, hallucinations, or severe depression 
[23]. As with any brain surgery, DBS surgery has potential complications like stroke or brain 
hemorrhage [23]. 
1.7 NEED FOR RESEARCH 
 Recent developments in Parkinson’s Disease research are giving researchers optimism 
that the disease can be defeated. PD is a complex neurodegenerative disease resulting from the 
death of dopamine producing cells in the substantia nigra [11]. What triggers the death of these 
cells remains unknown [11]. Studying genetics, epidemiology, and environmental factors all 
contribute to finding a cure. Identifying genes linked to PD fuels growth in understanding the 
disease process, revealing drug targets, improving early diagnosis, and developing animal models 
to mimic the nerve death in humans [11]. The National Institute of Health (NIH) released a 
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formal Parkinson’s Disease research agenda in 2000 stating that new technologies and discoveries 
in neuroscience are opening new doors to potential cures [11]. Halting the progression of PD, 
restoring lost function and even preventing the disease are becoming more realistic possibilities 
through advances in neuroimaging, gene array technologies, animal models, biomarkers and other 
modern scientific tools [11]. The National Institute of Neurological Disorders and Stroke 
(NINDS) is currently leading an initiative to better understand and diagnose PD, develop new 
treatments, and ultimately prevent PD [29]. In 2014, the NNIDS held a conference, labelled 
“PD2014”, bringing neuroscientists, physicians, public and private organization representatives, 
and PD patients together to develop a set of recommendations addressing the highest priorities for 
advancing research on PD [29]. In the topic of clinical research, one of the recommendations 
involves the use of “innovative outcome measures to evaluate motor and non-motor features, 
including patient- and clinician- reported outcomes that leverage emerging information 
technology (IT) opportunities, enhance sensitivity and specificity of measurement, and facilitate 
long-term follow-up of well-characterized cohorts” [30]. One of the approaches to address this 
research is an investigation of the feasibility and validity of “diverse methods of data collection 
including computerized tablet, smartphone, remote monitoring, and computerized adaptive 
testing” [30].  
1.8 MOBILE TECHNOLOGY 
  Difficulties remain in the reliability of clinically evaluated PD symptoms involving 
functioning in everyday life, long periods of time, and observing critical milestones throughout 
the course of the disease [12]. Fluctuating events like responses to medicine and incidents like 
falling are difficult for doctors to track and react to without constant monitoring. The evolving 
miniaturization, sophistication, proliferation, and accessibility of sensing technologies opens a 
new door to data collection beyond the doctor’s office by introducing novel methods for patient 
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monitoring [12]. Modern sensors embedded in every day devices can track and send important 
health information like motion, sleep patterns and heart rate to health professionals within 
minutes [12]. This can enhance treatment methods, preventative care, and drastically reduce the 
number of trips taken to the doctor’s office. With the rapid growth of these new technologies, the 
questions now faced are how to properly deploy them, what are the clinical needs, and how to 
leverage them to replace or enhance current clinical assessment tools. The ability to remotely 
capture symptom data and use it to optimize treatment strategies introduces a possibility to create 
closed loop treatment systems while producing valuable information for research [12]. For 
example, a wearable system may detect a change in step cadence associated with stride length, 
triggering a device designed to deliver proprioceptive cues for changing postural control and 
stepping pattern which could in turn prevent a fall [12]. Continuously monitoring PD symptoms 
may also be used to track and optimize the effectiveness of therapies, such as deep brain 
stimulation. 
1.8.1 Sensor Technology 
Modern mobile devices commonly contain sensors for interaction with the device and 
installed software applications. Evolving sensor technology has led to decreasing sensor sizes 
allowing for several sensors to be embedded in digital devices like smart phones and wearable 
technology. Smart devices like mobile phones, tables, and smart watches contain inertial sensors 
(accelerometer, gyroscope), GPS, and pedometers with high levels of accuracy for motion 
tracking. Other advanced wearable technologies contain sensors for monitoring respiratory rate, 
skin conductance, blood pressure, oximetry, and electrocardiography [12]. In addition to the high 
level of accuracy and wide range of capabilities, the sensors are low power enabling them to poll 
data for long periods of time. For instance, sleep medicine research has begun utilizing actigraphy 
(monitoring human rest/activity cycles) to supplant traditional methods like polysomnography 
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due to its validity, low cost, and ability to monitor patients at home [12]. Accelerometers and 
gyroscopes are well suited for the detection of PD motor symptoms such as tremor, bradykinesia, 
gait impairment, and motor complications, such as dyskinesia [12].  
1.8.2 Big Data Collection 
 The health care industry generates large amounts of data, primarily due to regulatory 
requirements, record keeping, and patient care [16] and biomedical research data is stored in 
varying formats, increasing the need to organize and understand the data to foster new discovery 
[31]. While most health care data are stored in hard copy form, the current trend is toward rapid 
digitization [16]. By definition, big data in health care refers to health data sets so large and 
complex that traditional data management tools and methods cannot easily manage the data, 
overwhelmed by the volume and diversity of data types [16]. However, recent technological 
advances are improving on the compilation, storage, and secured sharing of big data [32]. For 
instance, electronic medical record (EMR) systems are becoming more affordable and allow data 
to be exchanged more easily [32]. In 2014, the NIH published a Big Data to Knowledge (BD2K) 
initiative to maximize the use of big data in health care by defining how to extract value from 
data and create analytic tools needed to enhance the utility of the data [31]. A recommended 
approach from the NINDS PD2014 conference for progressing clinical research in PD is to 
“develop improved informatics capability to include investigation of how ‘big data’ may 
contribute to a fuller understanding of PD, a central repository for PD trial data, [and] a resource 
for trial design simulations” [30]. The medical experts and PD patients in attendance noted that 
making use of existing data sets is an efficient way to address questions related to the 
characterization of PD symptoms and progression [30]. They stressed the importance for a central 
body to manage the standardization of datasets, uniformly archive existing data, and provide a 
user-friendly end product [30]. Development of an information system for health data must 
	
	
16 
	
overcome barriers to use including access to data, ethical challenges, and de-identification of data 
[30]. Implementing data security measures to protect sensitive patient information is important to 
comply with HIPAA regulations. Many private-sector companies are developing applications and 
analytical tools that help patients, physicians, and other health care stakeholders identify value 
and opportunities with big data [32]. An evaluation of the marketplace in 2013 revealed over 200 
businesses created since 2010 are developing such tools to make better use of available health 
information [32]. Many research groups are in the process of assessing methods to probe 
individual motor and non-motor symptoms [12]. An opportunity exists to identify technologies 
and approaches with the most versatility, greatest ease of deployment, least patient and physician 
encumbrance, and lowest cost [12]. Choosing a platform for technology-based objective 
measurements (TOM) behind which developers and end-users can coalesce is key for developing 
applications for big data collection and analysis [12].  
1.9 RELATED WORK 
The evolution of digital technology has resulted in a surging interdisciplinary effort to 
explore novel applications in medical research. Researchers from electrical, computer, 
mechanical and biomedical backgrounds are working cohesively to design, build, and test 
systems intended to meet an abundance of clinical needs. The need for enhancing assessment 
tools for Parkinson’s Disease is no exception. Within the last 5 years, several methods have been 
proposed by researchers around the world to enhance PD research efforts by utilizing mobile 
technology and small sensors. The following examples demonstrate recent developments but only 
provide a small snippet of the many global research efforts.  
1.9.1 mPower 
In 2015, Sage Bionetworks launched an observational study using Apple’s ResearchKit 
library on iPhones to evaluate the feasibility of remotely collecting frequent information about 
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PD symptom severity on a daily basis [37]. Since the release of the iPhone application dubbed 
“mPower”, over 12,000 participants have enrolled [38]. The study is intended to gather data from 
any population, healthy patients and those affected by PD, to create a large database accessible to 
researchers interested in the data [37]. 
1.9.2 Kinesia 360 
 In January 2016, Great Lakes Neurotechnologies began clinical trials using their Kinesia 
360 product, a wearable technology-based device to objectively assess PD symptoms [39]. There 
are 45 PD patients enrolled in the clinical trial aimed to investigate the efficacy of the product to 
measure symptoms [39]. Kinesia 36 features a mobile app and wireless motion sensors worn on 
the wrist and ankle to measure tremor, dykinesias, and mobility during normal daily activities. 
The data collected is transferred to a cloud server where data reports are generated for clinician 
review [39]. 
1.9.3 Academic Research 
 In addition to interested research organizations, quantification of motor symptoms is a 
trending topic among academic researchers. A Master’s thesis produced by Michelle Vos at the 
University of Twente in the Netherlands involves the use of a glove containing inertial sensors to 
quantify tremor, bradykinesia and rigidity in PD patients by observing wrist angle, arm 
orientation, and movement [41]. The conclusion of the thesis showed promising results with the 
gloves ability to measure bradykinesia and rigidity symptoms [41]. Another study done by 
researchers at several universities in China [40] succeeded in creating a wrist worn device with a 
finger sensor attachment that has very a high correlation with the UPDRS evaluation performed 
by neurologists for bradykinesia tasks. Both studies were published in 2015 from universities in 
Europe and Asia, indicating the current global trend toward implementing mobile technology in 
medical research. 
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 CHAPTER 2 
 
OBJECTIVES 
Research groups around the world are attempting to tackle the challenge of leveraging 
mobile technology to enhance medical care. Difficulties arise when device engineers must take 
into consideration regulations not normally seen outside of the medical industry. This requires 
engineers and medical professionals working together to build a cohesive system optimized to 
meet medical needs and stay within FDA regulations while considering the boundaries of device 
capabilities. With the current treatment methods and medical care provided for those with 
Parkinson’s Disease, an opportunity exists to harness mobile device technology to provide much 
improved care. Sensor technology in common devices found in the everyday pockets of people 
across the nation have the potential to provide valuable insight regarding the progression of the 
disease and information normally unobtainable for clinicians.  
2.1 PROJECT GOAL 
The goal of this thesis is to design and develop a working prototype of a mobile 
application to be used for measuring the cardinal features of Parkinson’s Disease. The application 
should demonstrate the potential for sensors in commonly used consumer electronics to produce 
valuable clinical data for evaluating Parkinson’s Disease symptoms outside of a doctor’s office. 
By harnessing mobile technology already largely integrated into society, gathering large amounts 
of data for improved analysis becomes feasible. The clinical need for a quantitative assessment of 
PD motor symptom progression is clear. Designing a system to address this need and accomplish 
the project goal requires a set of comprehensive functional requirements and system 
specifications as listed below.  
Functional Requirements 
§ Record patient information (demographics, PD characteristics, etc.) 
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§ Provide a means for measuring tremor symptoms 
§ Provide a means for measuring gait symptoms 
§ Provide a means for measuring bradykinesia symptoms 
§ Store data on cloud server  
§ Perform analysis on measurements 
§ User friendly interface 
§ Secure data by requiring authentication to access 
§ Include a sign up process with eligibility requirements 
System Specifications 
§ iOS/watchOS application 
§ iPhone 6 (iOS 9.5.3/10) 
§ Apple Watch (watchOS 2.3.2/3) 
§ ResearchKit framework 
§ Amazon Web Services (AWS) S3 cloud storage 
§ Matlab 2015a for analysis 
§ CoreMotion framework to access hardware (sensors, touch screen) 
§ CoreData framework for data management and persistence 
§ SQLite Studio for accessing database file on computer 
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CHAPTER 3 
 
DESIGN OVERVIEW  
3.1 SYSTEM OVERVIEW 
 Designing a digital system for clinical purposes requires consideration of the patient, 
doctor, and protection of health information. Development of the user interface should ensure 
ease of use, especially when considering a target audience that is less adaptive to new technology. 
The front-end system design considers usability, aesthetics, and instruction deliverance to assist 
in proper use and comfort while using the application. Back-end design focuses on data 
persistence, speed, security, and data formatting to ensure the necessary precautions are taken 
with the transportation of digital health information while keeping the data in a format readily 
used for analysis.    
 The devices used for development of the application are the iPhone 6 and the Apple 
Watch. Selection of the hardware was influenced by ease of integration into St. Jude Medical’s 
existing patient care technology, ease of use, and device prevalence among smart device 
consumers. The iPhone provides data persistence, sensor recordings, and central processing while 
the Apple Watch provides a secondary wearable source for sensor recordings.  
 
Figure 1. High level system overview 
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Figure 1 shows the overview of system operation from the user at home with the Apple Watch 
and iPhone to collect data related to PD symptoms, uploading the data to a cloud database server, 
and the downloading of data by doctors and clinicians for analysis. The Apple Watch is worn by 
the user to collect motion data from the arm and transfers that data to the iPhone via Bluetooth. 
The iPhone provides both data collection and data management by uploading the collected data to 
a secure cloud server via an internet connection through WiFi or mobile broadband. Once 
uploaded, the data may be downloaded by an authenticated user, typically a clinician or doctor, 
and manipulated using data analysis tools to extract valuable parameters.  
3.1.1 Design Workflow 
 
 The design workflow centers around the flow of data, beginning with collection from the 
patient and ending with deliverance to the doctor, clinic, or data analyzer. Initial steps of data 
collection involve instructing the user to navigate through the application, starting and stopping 
sensor input, and storing sensor output. Deliverance of data involves moving the data from the 
local device to a remote location while maintaining data integrity. The application design begins 
with creating a user-friendly interface easily understood to new users. Instructions guide the user 
through all sections of the application from the signup process to the performance of tasks. 
During each task, sensors in the iPhone and Apple Watch are turned on to collect motor-related 
symptoms data and store the data locally on the iPhone. Sensory data may be uploaded to an 
Amazon Web Services (AWS) server cloud server by pressing an “Upload Data” button easily 
found in the application. Once the data has been uploaded to AWS cloud storage, the data may be 
accessed by an authenticated user from a computer and downloaded for analysis.  
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3.1.2 Sensors 
  The sensors used in the application focus on collecting motion data related to the 
cardinal features of PD. The accelerometer, gyroscope, magnometer, and touch screen sensors are 
used during instructed tasks similar to those performed in the UPDRS assessment. The iPhone 6 
features a 6-axis gyroscope-accelerometer combo unit, an additional 3-axis accelerometer, 
touchscreen controller, magnometer, and GPS. The Apple Watch features a 6-axis gyroscope-
accelerometer combo unit, pressure-sensitive touchscreen controller, and heart rate monitor. A 
full list of sensors found in the Apple Watch and iPhone 6 is shown in Table 4.  
Table 4. Sensors in the Apple Watch and iPhone 6 
 Apple Watch iPhone 6 
Accelerometer X X 
Gyroscope X X 
Microphone X X 
Heart Rate Sensor X  
GPS  X 
Touch ID (Biometric sensor)  X 
Proximity Sensor (i.e. phone near ear)  X 
Ambient Light Sensor X X 
Camera/Video Camera  X 
Magnetometer  X 
Touch Sensor X X 
 
The symptoms targeted in this application are primarily motion-based making the motion-related 
sensors most useful. The accelerometer and gyroscope of the Apple Watch or iPhone 6 are used 
during the gait and tremor tasks. Continuous data samples from these sensors reveal important 
information regarding the amplitude and oscillation frequency normally observed visually by a 
neurologist while performing a clinical assessment. Figure 2 shows the axes of rotation and 
movement for the gyroscope and accelerometer. Oscillation patterns on each axis are recorded to 
be analyzed and compared to oscillation frequencies characteristic to PD.  
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Figure 2. iPhone axes for the gyroscope and accelerometer [19] 
 
The accelerometer and gyroscope in the Apple Watch and iPhone offer high accuracy and 
sensitivity. Apple does not openly release specifications for their devices, leaving it up to reverse-
engineering companies to find out embedded chip specifications used in the devices such as the 
accelerometer.  Device teardowns performed by iFixit [17] and Chipworks [18] reveal the 
accelerometer and gyroscope part numbers used in the devices to learn about the specifications. 
The specifications for the accelerometers and gyroscope in the iPhone 6 are listed in Table 5. 
Table 5. Accelerometer/Gyroscope specifications for iPhone 6 [36] 
Parameter Bosch BMA280 InvenSense MPU-6500 Units 
Sensor type Accelerometer Accel/Gyro Combo - 
ADC range 14 16 bit 
Acceleration range ±2, ±4, ±8, ±16 ±2, ±4, ±8, ±16 g 
Maximum sensitivity 4096 16684 LSB/g 
Temperature sensitivity 0.015 0.026 %/K 
Cross axis sensitivity 1 2 % 
Nonlinearity 0.5 0.5 % 
Output data rate 2000 4000 Hz 
Cold start up time 3 30 ms 
Sleep mode start up time 1 20 ms 
Accelerometer start up time from sleep mode 1.3 20 ms 
Accelerometer supply current in normal mode 130 450 µA 
Accelerometer supply current in low power mode 1 6.5 7.27 µA 
Accelerometer supply current in low power mode 2 66 18.65 µA 
Sleep mode current 2.1 6 µA 
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The iPhone 6 and Apple Watch both feature touch screen displays capable of accurately 
measuring tapping motion as related to PD. The iPhone 6 has a capacitive multi-touch touch 
screen with excellent touch-display response time. While the touch screen primarily serves as the 
navigation utility, it also provides a valuable sensor for recording PD motor symptoms related to 
bradykinesia. The 4.7” touch screen on the iPhone 6 is appropriately sized for interaction during 
the performance of an activity intended to measure bradykinesia symptoms. Figure 3 shows the 
touch screen sensor on the iPhone. 
 
Figure 3. iPhone touch screen sensor [36] 
3.1.3 Software 
 The software used for the application is largely dependent on the hardware. The 
application runs on Apple’s iOS mobile device operating system (OS) for the iPhone and the 
watchOS software dedicated for the Apple Watch. Apple devices require the use of the 
proprietary device OS eliminating the need for a software comparison process. The application 
was built for iOS 9.5.3 on the iPhone 6 and watchOS 2.3.2 on the Apple Watch. In order to 
maintain compatibility with future iterations of iOS and watchOS, the application has been 
converted to provide compatibility for iOS 10 and watchOS 3.0. The cloud storage utilized is the 
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AWS Simple Storage Service (S3). Amazon S3 provides easy to use object storage for developers 
and offers HIPAA compliance for securely storing protected health information (PHI). 
3.2 APPLICATION DESIGN 
 Development of the application required the use of Apple’s proprietary integrated 
development environment (IDE) Xcode compatible only on Mac OS X. In addition to providing 
the environment for code editing, Xcode is used for debugging, project file management, 
compiling, and version control. Developing code for apple devices requires the use of Apple’s 
proprietary coding languages. Objective-C was the standard language used for Apple 
development until the release of Swift in 2014. Most long-standing applications seen on Apple 
devices are written in Objective-C. Only recently has Swift gained traction with new applications 
being written in Swift and old applications beginning to convert. The language used for 
development of the application discussed here is Swift with frameworks included in the build 
written in Objective-C. The included frameworks provide application program interfaces (API) 
enabling the use of hardware and software packages by the application. Accessing sensors, saving 
data to local storage, uploading data to cloud servers, and manipulating data formats are all 
examples of functions that may be supplemented using an associated framework. The frameworks 
used in the application and their corresponding languages are listed in Table 6. 
Table 6. Frameworks included in the application 
Framework Language 
WatchKit Swift 
HealthKit Swift 
ResearchKit Objective-C 
SwiftyJSON Objective-C/Swift 
CoreData Swift 
CoreMotion Swift 
AWS Objective-C/Swift 
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In 2015, Apple released ResearchKit, an open source framework intended to provide medical 
researchers with a platform to conduct studies using Apple technology [33]. The ResearchKit 
framework provides a model for instructing users through various tasks accessing the sensors on 
the mobile device, making it a valuable tool for the development of this application. ResearchKit 
also works seamlessly with HealthKit, a framework connected to the Health app integrated into 
iOS, providing health-related patient data potentially relevant to the medical topic focused on by 
a ResearchKit application such as height, weight, age, or skin tone [33].  
 The WatchKit framework is required for the use of the Apple Watch with an iPhone 
application. Currently, standalone Apple Watch applications cannot be developed. Instead, a 
watch “extension” application is installed on the Apple Watch “paired” to the iPhone on which 
the main application is installed. The WatchKit framework provides functions for initiating and 
maintaining communication between the Apple Watch and the iPhone while the application is 
open. This is important for relaying sensor information collected on the watch to the iPhone after 
completion of the motor tasks performed using the watch.  
 The CoreMotion framework allows the application to receive motion data from the 
hardware and process that data. Pre-defined classes and objects provide the means for pulling the 
hardware output into the software for manipulation in the application. CoreMotion restrictions 
allows for sampling from the motion sensors at a rate of up to 100Hz. 
 The CoreData and AWS frameworks are both used for the storage of data. CoreData is 
used for local storage on the iPhone where sensor samples are stored after task completion before 
uploading to the cloud server. The AWS framework provides the API needed to pass information 
stored using CoreData onto the AWS cloud servers.  
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3.2.1 Key Components 
 The user-facing portion of the application consists of 3 key components: tasks, patient 
information, and data analysis. Upon opening the application, the user is presented with a 
welcome page and the option to sign up to participate in the study affiliated with the application. 
After signing up, the user interface (UI) consists of 3 main tabs for each of the 3 components. At 
any time, the user may choose to opt out of the study.  
 The sign up process for the application involves inputting personal information and 
health information related to the user’s current PD treatment. An eligibility form is completed to 
determine if the user meets the inclusion criteria for participation in the application. The 
following criteria must be met to be eligible: 
§ Over 18 years of age 
§ Diagnosed with Parkinson’s Disease 
§ Neurologically stable 
§ Able to understand the study and informed consent form 
§ Not participating in a clinical investigation that includes an active arm treatment 
§ Able to perform the motor tasks required for the study 
§ Able to use the iPhone and Apple Watch apps. 
If the user meets the eligibility criteria, demographic and PD characteristic information is 
collected as shown in Figure 4. This data is stored securely and presented to the user on the 
profile tab of the UI shown in Figure 5. This provides a visual confirmation for the user to ensure 
the information input during the signup process is correct. The profile page also includes a button 
for uploading data collected during the tasks to a secure cloud server.  
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Figure 4. Application signup process 
 
 
Figure 5. Profile tab of the application 
A list of the available tasks is presented after navigating to the activities tab as seen in 
Figure 6. Tasks may be selected by tapping on the respective list button, after which instructions 
are presented to guide the user through the completion of the task. Each task takes no longer than 
5 minutes to complete with the shortest task taking approximately 10 seconds. Tasks intended to 
collect motor symptom related data contain visual instruction steps indicating proper performance 
of the selected task. After navigating through the instructional steps, an audible countdown 
precedes the initiation of the sensors. The “active step” is the portion of each task dedicated to 
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collecting data from the sensors while the user performs an indicated motion. The last step of 
each tasks presents a confirmation of completion and allows the user to return back to the main 
screen. 
 
Figure 6. Activities tab of the application 
Following completion of each of the motor tasks, the immediate results of low level 
analysis are displayed on the analysis tab as shown in Figure 7. Data collected from the sensors is 
processed on the iPhone to be translated into an estimated UPDRS score for each task. In order to 
estimate the UPDRS score, a correlation between the sensor output and neurologist-based scores 
will need to be developed through validation testing. After the data has been processed locally, 
the option to upload to the cloud server becomes available via a button on the profile tab. Once 
uploaded, the data may be accessed for viewing and further analysis by an authenticated user on a 
computer. 
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5.1.2 Clinical Trials  
 With a refined user interface and verified sensor efficacy, a clinical study incorporating 
PD patients should be performed to develop algorithms to calculate UPDRS scores relative to 
those given by neurologists. A clinical study with PD patients may also provide valuable 
feedback regarding the ease of use of the application.  
5.1.3 Application Improvements 
As research progresses in the use of mobile devices for PD symptom assessment, new 
methods may prove to be more effective for providing insight on the progression of the disease. 
With this in mind, the application presented here is designed to simplify improvements with 
content and methods for data analysis. Three tasks were incorporated in the application to 
demonstrate how the sensors in the mobile devices can be utilized to gather motor related 
symptom data. This included leveraging the inertial sensors, touch screen, and GPS for tremor, 
bradykinesia, and postural stability assessment. Other sensors and additional tasks may be 
seamlessly integrated due to the modular design of the application. For example, to provide 
insight on vocal symptoms characteristic to PD, a new task may direct the user to speak into the 
microphone to gather voice data to be analyzed.  
  
	
	
50 
	
BIBLIOGRAPHY 
[1] Jankovic, J. “Parkinson’s Disease: Clinical Features and Diagnosis.” Journal of Neurology, 
Neurosurgery & Psychiatry 79, no. 4 (April 1, 2008): 368–76. 
doi:10.1136/jnnp.2007.131045. 
 
[2] Kalia, Lorraine V, and Anthony E Lang. “Parkinson’s Disease.” The Lancet 386, no. 9996 
(September 4, 2015): 896–912. doi:10.1016/S0140-6736(14)61393-3. 
 
[3] Carranza, Michael, Madeline R. Snyder, Jessica Davenport Shaw, and Theresa A. Zesiewicz. 
Parkinson’s Disease: A Guide to Medical Treatment. SEEd, 2013. 
 
[4] Health Reference Series: Brain Disorders Sourcebook (4). Detroit, US: Omnigraphics, 2015. 
http://site.ebrary.com/lib/alltitles/docDetail.action?docID=11062704. 
 
[5] “Parkinson’s Disease-Symptoms.” WebMD. Accessed November 17, 2016. 
http://www.webmd.com/parkinsons-disease/tc/parkinsons-disease-symptoms. 
 
[6] “Primary Motor Symptoms - Parkinson’s Disease Foundation (PDF).” Accessed November 
17, 2016. http://www.pdf.org/symptoms_primary. 
 
[7] Perlmutter, Joel S. “Assessment of Parkinson Disease Manifestations.” Current Protocols in 
Neuroscience / Editorial Board, Jacqueline N. Crawley ... [et Al.] CHAPTER (October 
2009): Unit10.1. doi:10.1002/0471142301.ns1001s49. 
 
[8] Goetz, Christopher G., Werner Poewe, Olivier Rascol, Cristina Sampaio, Glenn T. Stebbins, 
Carl Counsell, Nir Giladi, et al. “Movement Disorder Society Task Force Report on the 
Hoehn and Yahr Staging Scale: Status and Recommendations” Movement Disorders 19, 
no. 9 (September 1, 2004): 1020–28. doi:10.1002/mds.20213. 
 
[9] Williams, Ray. “Parkinson Disease.” In Parkinson Disease, edited by Waynertin, Oksana 
Suchowersky, Katharina Kovacs Burns, and Egon Jonsson, 1–7. Wiley-VCH Verlag 
GmbH & Co. KGaA, 2010. 
http://onlinelibrary.wiley.com/doi/10.1002/9783527629480.ch1/summary. 
 
[10] Chaudhuri, K Ray, Christopher G Clough, and Kapil D Sethi. Fast Facts : Fast Facts: 
Parkinson’s Disease : Parkinson’s Disease (3). Oxford, GB: Health Press, 2011. 
http://site.ebrary.com/lib/alltitles/docDetail.action?docID=10480469. 
 
[11] “Parkinson’s Disease Research Agenda.” Accessed November 17, 2016. 
http://www.ninds.nih.gov/about_ninds/plans/nihparkinsons_agenda.htm#Parkinson. 
 
[12] Espay, Alberto J., Paolo Bonato, Fatta B. Nahab, Walter Maetzler, John M. Dean, Jochen 
Klucken, Bjoern M. Eskofier, et al. “Technology in Parkinson’s Disease: Challenges and 
Opportunities.” Movement Disorders: Official Journal of the Movement Disorder Society 
31, no. 9 (September 2016): 1272–82. doi:10.1002/mds.26642. 
 
[13] Giuffrida, Joseph P., David E. Riley, Brian N. Maddux, and Dustin A. Heldman. “Clinically 
Deployable KinesiaTM Technology for Automated Tremor Assessment.” Movement 
Disorders 24, no. 5 (April 15, 2009): 723–30. doi:10.1002/mds.22445. 
	
	
51 
	
 
[14] Poushter, Jacob. “Smartphone Ownership and Internet Usage Continues to Climb in 
Emerging Economies.” Pew Research Center’s Global Attitudes Project, February 22, 
2016. http://www.pewglobal.org/2016/02/22/smartphone-ownership-and-internet-usage-
continues-to-climb-in-emerging-economies/. 
 
[15] Giansanti, Daniele, Velio Macellari, and Giovanni Maccioni. “Telemonitoring and 
Telerehabilitation of Patients with Parkinson’s Disease: Health Technology Assessment 
of a Novel Wearable Step Counter.” Telemedicine and E-Health 14, no. 1 (February 1, 
2008): 76–83. doi:10.1089/tmj.2007.0019. 
 
[16] Raghupathi, Wullianallur, and Viju Raghupathi. “Big Data Analytics in Healthcare: Promise 
and Potential.” Health Information Science and Systems 2 (2014): 3. doi:10.1186/2047-
2501-2-3. 
 
[17] “Inside the Apple Watch: Technical Teardown Blog | Chipworks.” Accessed November 18, 
2016. http://www.chipworks.com/about-chipworks/overview/blog/inside-the-apple-
watch-technical-teardown-blog. 
 
[18] “iPhone 6 Teardown - iFixit.” Accessed November 18, 2016. 
https://www.ifixit.com/Teardown/iPhone+6+Teardown/29213. 
 
[19] “Motion Events.” Accessed November 18, 2016. 
https://developer.apple.com/library/content/documentation/EventHandling/Conceptual/E
ventHandlingiPhoneOS/motion_event_basics/motion_event_basics.html. 
 
[20] Davie, C. A. “A Review of Parkinson’s Disease.” British Medical Bulletin 86, no. 1 (June 1, 
2008): 109–27. doi:10.1093/bmb/ldn013. 
 
[21] Samii, Ali. “Essential Tremor.” In Encyclopedia of Neuroscience, edited by Marc D. Binder, 
Nobutaka Hirokawa, and Uwe Windhorst, 1155–56. Springer Berlin Heidelberg, 2009. 
http://link.springer.com/referenceworkentry/10.1007/978-3-540-29678-2_3091. 
 
[22] Goetz, Christopher G., and Cristina Sampaio. “Assessment of Non-Motor Features of 
Parkinson’s Disease: Scales and Rating Tools.” In Parkinson’s Disease, edited by C. 
Warren Olanow MD FRCPC, Fabrizio Stocchi MD, and Anthony E. Lang MD FRCPC, 
111–25. Blackwell Publishing Ltd., 2011. 
http://onlinelibrary.wiley.com/doi/10.1002/9781444397970.ch10/summary. 
 
[23] “What Is Parkinson’s? - Parkinson’s Western Australia.” Accessed November 22, 2016. 
http://www.parkinsonswa.org.au/what_is_parkinsons. 
 
[24] “The Unified Parkinson’s Disease Rating Scale (UPDRS): Status and Recommendations.” 
Movement Disorders 18, no. 7 (July 1, 2003): 738–50. doi:10.1002/mds.10473. 
 
[25] Tuite, Dr. Paul, Cathi Thomas, and Laura Ruekert. Parkinson’s Disease: A Guide to Patient 
Care. New York, US: Springer Publishing Company, 2009. 
http://site.ebrary.com/lib/alltitles/docDetail.action?docID=10286257. 
 
	
	
52 
	
[26] Goetz, Christopher G., Barbara C. Tilley, Stephanie R. Shaftman, Glenn T. Stebbins, Stanley 
Fahn, Pablo Martinez-Martin, Werner Poewe, et al. “Movement Disorder Society-
Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): 
Scale Presentation and Clinimetric Testing Results.” Movement Disorders: Official 
Journal of the Movement Disorder Society 23, no. 15 (November 15, 2008): 2129–70. 
doi:10.1002/mds.22340. 
 
[27] Simuni, Tanya, and Rajesh Pahwa. Parkinson’s Disease. Cary, US: Oxford University Press, 
USA, 2009. http://site.ebrary.com/lib/alltitles/docDetail.action?docID=10375051. 
 
[28] “Parkinson’s Disease Brochure.” Accessed November 7, 2016. 
http://permanent.access.gpo.gov/gpo71661/parkinsons-disease-brochure.pdf. 
 
[29] “NINDS | Parkinson’s Disease | Hope Through Research.” Accessed November 27, 2016. 
http://www.ninds.nih.gov/disorders/parkinsons_disease/detail_parkinsons_disease.htm. 
 
[30] “NINDS Parkinson’s Disease 2014 Research Recommendations.” Accessed November 27, 
2016. http://www.ninds.nih.gov/research/parkinsonsweb/PD2014/2014-NINDS-PD-
Recommendations.htm#develop_improved. 
 
[31] Margolis, Ronald, Leslie Derr, Michelle Dunn, Michael Huerta, Jennie Larkin, Jerry 
Sheehan, Mark Guyer, and Eric D. Green. “The National Institutes of Health’s Big Data 
to Knowledge (BD2K) Initiative: Capitalizing on Biomedical Big Data.” Journal of the 
American Medical Informatics Association 21, no. 6 (November 1, 2014): 957–58. 
doi:10.1136/amiajnl-2014-002974. 
 
[32] Center for US Health System Reform Business Technology Office. “The ‘big 
Data’  Revolution in Healthcare.” Accessed November 1, 2016. 
http://www.pharmatalents.es/assets/files/Big_Data_Revolution.pdf. 
 
[33] “Apple - Press Info - Apple Introduces ResearchKit, Giving Medical Researchers the Tools 
to Revolutionize Medical Studies.” Accessed November 28, 2016. 
http://www.apple.com/pr/library/2015/03/09Apple-Introduces-ResearchKit-Giving-
Medical-Researchers-the-Tools-to-Revolutionize-Medical-Studies.html. 
 
[34] “SQLiteStudio.” Accessed November 29, 2016. http://sqlitestudio.pl/. 
 
[35] “Gesture Recognizers.” Accessed December 2, 2016. 
https://developer.apple.com/library/content/documentation/EventHandling/Conceptual/E
ventHandlingiPhoneOS/GestureRecognizer_basics/GestureRecognizer_basics.html. 
 
[36] “Comparing the InvenSense and Bosch Accelerometers Found in the iPhone 6 | Chipworks.” 
Accessed December 2, 2016. https://www.chipworks.com/about-
chipworks/overview/blog/comparing-invensense-and-bosch-accelerometers-found-
iphone-6. 
 
[37] Bot, Brian M., Christine Suver, Elias Chaibub Neto, Michael Kellen, Arno Klein, 
Christopher Bare, Megan Doerr, et al. “The mPower Study, Parkinson Disease Mobile 
Data Collected Using ResearchKit.” Scientific Data 3 (March 3, 2016). 
doi:10.1038/sdata.2016.11. 
	
	
53 
	
 
[38] “Parkinson’s mPower App Celebrates Milestone - 12,000 Registered Users - and Upgrade at 
Apple Product Launch.” Parkinson’s News Today, March 28, 2016. 
http://parkinsonsnewstoday.com/2016/03/28/parkinsons-mpower-app-celebrates-
milestone-12000-registered-users-upgrade-apple-product-launch/. 
 
[39] Earhart, Amelia. “Kinesia 360TM Product Overview.” Kinesia, October 20, 2014. 
http://glneurotech.com/kinesia/products/kinesia-360/. 
 
[40] Dai, Houde, Haijun Lin, and Tim C Lueth. “Quantitative Assessment of Parkinsonian 
Bradykinesia Based on an Inertial Measurement Unit.” BioMedical Engineering OnLine 
14 (July 12, 2015). doi:10.1186/s12938-015-0067-8. 
 
[41] Vos, M. C. P. M. “Quantification of Parkinsonian Tremor, Bradykinesia and Rigidity Using 
the PowerGlove in Combination with a Force Sensor.” Info:eu-
repo/semantics/masterThesis, September 3, 2015. http://essay.utwente.nl/68089/. 
 
[42] Thenganatt, Mary Ann, and Elan D Louis. “Distinguishing Essential Tremor from 
Parkinson’s Disease: Bedside Tests and Laboratory Evaluations.” Expert Review of 
Neurotherapeutics 12, no. 6 (June 2012): 687–96. doi:10.1586/ern.12.49. 
 
 
 
 
	
	
54 
	
APPENDICES 
APPENDIX A: USER MANUAL 
 
 
 
USER MANUAL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
myNeuro 
  
	
	
55 
	
Table of contents 
 
1.0 GENERAL INFORMATION 
 1.1 Introduction 
 1.2 Requirements 
 1.3 Eligibility 
2.0 INSTALLATION 
 2.1 Installing the App 
3.0 USING THE APP 
 3.1 Starting the Application 
 3.2 Joining the Study 
 3.3 Patient Profile 
 3.4 Activities 
  3.4.1 Questionnaire 
  3.4.2 Tremor 
  3.4.3 Bradykinesia 
  3.4.4 Gait 
  3.4.5 Tremor (Watch) 
  3.4.6 Bradykinesia (Watch) 
 3.5 Analysis 
4.0 ACCESSING DATA 
 4.1 Amazon Web Services 
 4.2 Offline 
 4.3 SQLiteStudio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
	
	
56 
	
1.0 GENERAL INFORMATION 
 
1.1 Introduction 
 
The myNeuro application is intended for use in a clinical environment by Parkinson’s Disease 
patients under the supervision of a neurologist. The application is not intended to provide 
diagnostic information. Data gathered by the application is intended for research purposes only.  
 
1.2 Requirements 
 
Hardware Requirements: 
- iPod Touch 5/iPhone 5 or greater 
- Apple computer (MacBook Pro, MacBook Air, iMac, etc.) 
- Apple Watch (optional) 
Software Requirements: 
- Xcode 7.3.1 or greater 
- iOS 9.3.5 or greater 
- watchOS 2.2.2 or greater 
- OS X 10.11.6 or greater 
Other Requirements: 
- Apple developer’s license 
- Amazon Web Services (AWS) account 
 
1.3 Eligibility 
 
The myNeuro app is only intended for use with users who meet the following inclusion criteria: 
 
- Over 18 years of age 
- Diagnosed with Parkinson’s Disease 
- Neurologically stable 
- Able to understand the study and informed consent form 
- Not participating in a clinical investigation that includes an active arm treatment 
- Able to perform the motor tasks required for the study 
- Able to use the iPhone and Apple Watch apps 
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2.0 INSTALLATION 
 
2.1 Installing the App 
 
The myNeuro application is currently in a development phase and is not available to consumers 
on the App Store. A development version of the app can be installed on a compatible device using 
Xcode on an Apple computer. There are 2 methods to install the app: 
 
Method 1: Build the app and install 
1. Download the source code for the application here.  
2. After downloading, unzip the archive and open the “.xcodeproj” file in Xcode.  
3. In the Xcode top menu bar, go to Xcode > Preferences and navigate to the Accounts 
Tab. Add your Apple ID by clicking the plus sign in the lower left corner and choose 
“Add Apple ID…” and login to your account. 
4. With the myNeuro project file selected in the left pane, select each of the Targets 
(myNeuro, neuroWatch, neuroWatch Extension), go to the General tab, and change 
the Team to your developer account in the Identity section. Do this for the 
ResearchKit project file and target as well. 
5. Change the bundle identifiers in the following locations: 
a. myNeuro > Targets > myNeuro > General > Bundle Identifier 
com.SJM.myNeuro.[YOURNAME] 
b. myNeuro > Targets > neuroWatch > General > Bundle Identifier 
com.SJM.myNeuro.[YOURNAME].watchkitapp 
c. myNeuro > Targets > neuroWatch Extension > General > Bundle Identifier 
com.SJM.myNeuro.[YOURNAME].watchkitapp.watchkitextension 
d. myNeuro > neuroWatch > Info.plist > WKCompanionAppBundleIdentifier 
com.SJM.myNeuro.[YOURNAME] 
e. myNeuro > neuroWatch Extension> Info.plist > NSExtension > 
NSExtensionAttributes > WKAppBundleIdentifier 
com.SJM.myNeuro.[YOURNAME].watchkitapp 
6. Plug in your device and select it as the build destination by going to Product > 
Destination and selecting your device. 
7. Ensure the myNeuro app is selected if using the app without an Apple Watch. Select 
the neuroWatch app if an Apple Watch is being used.  
8. Select the myNeuro project file in the left panel and click the “Fix Issue” button by 
the alert under the Team tab. This will generate a code signing signature for the app. 
9. Click the “Run” button to build and install the app. This will run the app in debug 
mode while the device is plugged in. Stop debug mode by clicking the stop button 
before unplugging the device.  
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Method 2: Install using the “.ipa” application file 
NOTE: The device ID must be entered on the Apple Developer account linked to the 
myNeuro application at the application build time. Failing to do so will prevent the app from 
installing on the device. Instructions for finding the device ID can be found here. 
 
The application can be downloaded here by choosing the most recent myNeuro app or 
neuroWatch app and downloading the “.ipa” application file. Once downloaded, follow these 
instructions to install the application: 
1. Plug in a compatible device into the Apple Computer with Xcode installed.  
2. When prompted on the device to trust the computer, choose “Trust”. 
3. Open Xcode and ensure your device has been connected.  
4. With Xcode open, go to Window > Devices. Ensure your connected device is listed 
on the left panel. 
5. Select the desired device. Under the Installed Applications section, click the “+” 
symbol and open the “.ipa” application file. 
6. Xcode will validate and install the application on the device. 
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3.0 USING THE APP 
 
3.1 Starting the Application 
 
myNeuro	app	installed	on	
iPhone.	Press	the	app	icon	to	
start	the	app.	
myNeuro	splash	screen	after	
app	has	started.	App	
contents	are	loading.	
Starting	page	of	the	app.	
Slider	style	pages	with	
information	about	the	app	
and	a	Join	Study	button.	
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3.2 Joining the Study 
  
Screen	displayed	if	user	
meets	eligibility	
requirements.	Button	
to	continue	on	to	study.	
Screen	displayed	if	user	
does	not	meet	eligibility	
requirements.		
Welcome	information	
during	the	visual	
consent	process.	
Eligibility	screen	to	
determine	if	the	user	
meets	the	inclusion	
criteria.	
Privacy	information	
during	the	visual	
consent	process.	
 
Data	use	information	
during	the	visual	
consent	process.	
 
Time	commitment	
information	during	the	
visual	consent	process.	
 
Data	Gathering	
information	during	the	
visual	consent	process.	
 
Study	task	information	
during	the	visual	
consent	process.	
 
Withdrawing	
information	during	the	
visual	consent	process.	
 
Review	consent	form.	
User	must	agree	to	the	
consent	form	to	
participate.	
Study	survey	
information	during	the	
visual	consent	process.	
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Enter	passcode	to	protect	
patient	information.	
Passcode	will	need	to	be	
entered	to	open	the	app.	
 
Patient	has	completed	
the	consent	review	
process.	
 
If	device	has	TouchID	
capabilities,	gather	a	
fingerprint.	
 
Gather	DBS	
configuration	info	if	
DBS	implanted.	
 
Prompt	displayed	to	
confirm	user	agrees	to	
consent	form.	
Gather	user’s	full	name	
after	they’ve	agreed	to	
the	consent	form.		
Gather	user’s	signature	
to	confirm	they’ve	
reviewed	the	consent	
form.	
Screen	displayed	if	user	
disagrees	to	the	
consent	form.	
Gather	patient	
Parkinson’s	Disease	
characteristics.	(top)	
 
Gather	patient	
Parkinson’s	Disease	
characteristics.	
(bottom)	
Gather	patient	
demographic	information.	
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3.3 Patient Profile 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Patient full name: Displays the full name of the patient. 
2. Upload Data button: Uploads the Core Data data store to a secure Amazon S3 bucket. 
Additional data is uploaded if the switches are on (see 4 and 5). 
3. Progress Bar: Shows the status of the current data upload. 
4. Backup JSON Files switch: When on, data uploads will include individual JSON files 
from task results (i.e. accelerometer, device motion, etc.) 
5. Backup with DynamoDB switch: When on, data uploads will also upload Core Data table 
entries to a secure Amazon DynamoDB database. Note that this will require much longer 
to complete the upload and the upload status will not be reflected by the progress bar. 
6. Leave Study button: Withdraws the current participant from the study. Any data gathered 
will remain stored on the device. Use this to reset the study for a new patient. 
7. Patient Demographic information and PD Characteristics: Displayed the demographic 
information and PD Characteristics gathered during the onboarding process. 
  
5 
 
7 
 
1 
3 
2 
4 
 
6 
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3.4 Activities 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Questionnaire: Gathers information regarding the patient’s Parkinson’s Disease 
symptoms and the impact they have on their daily life. 
2. Tremor: User performs several motions tasks relating to resting, kinetic, and postural 
tremor. 
3. Bradykinesia: User performs a tapping task relating to bradykinesia symptoms. 
4. Gait: User performs a gait and balance task relating to gait symptoms. 
5. Tremor (Watch): User performs several motion tasks relating to resting, kinetic and 
postural tremor using the Apple Watch. 
6. Bradykinesia: User performs a tapping task relating to bradykinesia symptoms on the 
Apple Watch. 
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3.4.1 Questionnaire 
 
Queston1	 Question	2	 Question	3	Questionnaire	initial	
screen.	
Question	5	
 
Completion	screen.	
 
Question	4	
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3.4.2 Tremor 
 
 
 
 
Tremor	task	description	
screen.	
 
Step	1	 Step	2	
 
Tremor	task	
introduction	screen.	
Step	4	 Step	5	 Step	6	Step	3	
Step	8	 Step	9	 Completion	screen.	Step	7	
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3.4.3 Bradykinesia 
  
Bradykinesia	task	
description	screen.	
Step	1	 Step	2	Bradykinesia	task	
introduction	screen.	
Completion	screen.	
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3.4.4 Gait 
  
Gait	and	Balance	task	
description	screen.	
Countdown	 Step	1	Gait	and	balance	task	
introduction	screen.	
Step	3	
 
Completion	screen.	
 
Step	2	
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3.4.5 Tremor (Watch) 
 
 
Tremor	Watch	task	
description	screen.	
 
Step	1	 Step	2	Tremor	Watch	task	
introduction	screen.	
Step	4	 Step	5	 Step	6	Step	3	
Step	8	 Step	9	 Completion	screen.	Step	7	
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3.4.6 Bradykinesia (Watch) 
 
  
Bradykinesia	Watch	
task	description.	
Watch	connect	screen	 Waiting	for	task	to	
finish	screen.	
Bradykinesia	Watch	
task	introduction	
screen.	
Completion	screen.	
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3.5 Analysis (Under Development) 
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4.0 ACCESSING DATA 
 
4.1 Amazon Web Services (AWS) 
 
Data from the study may be uploaded to AWS (Amazon Web Services) storage either via files to 
an S3 bucket or individual table rows to a DynamoDB database. After pressing the Upload Data 
button in the Profile tab, the Core Data data store (SQLite database) is uploaded to the AWS S3 
bucket. Switches in the Profile tab also enable/disable individual JSON files from task results and 
DynamoDB backing in addition to the Core Data data store upload. Any uploaded data can be 
accessed by following these instructions: 
 
1. Login to the AWS console (https://aws.amazon.com/console/) using the AWS account.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amazon S3:  
 
1. On the top menu bar, navigate to Services > S3 
 
 
 
 
 
 
 
 
2. Click the “myneuro” bucket 
 
 
 
 
 
 
 
3. Core Data data stored are uploaded to a folder titled with the date and time of the upload. 
Select the folder containing the file you want to download to your computer. Then double 
click the file to download. 
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NOTE: “.db” files can be opened using the SQLiteStudio program downloadable for free from 
http://sqlitestudio.pl/. This program can also export individual table as other file formats 
(i.e. CSV) for processing with data analysis programs. 
 
4.2 Offline 
 
1. Plug in the device and open Xcode.  
2. In the top menu bar, go to Window > 
Devices 
3. Select the device on the left panel 
4. In the “Installed Apps” section, select the 
myNeuro application 
5. Click the gear icon below and choose 
“Download container”. Choose a location to save. This will save the app data to a 
“.xcappdata” file.  
6. A finder window containing the file should open automatically. If not, navigate to the 
folder containing the container. 
7. Right click the file and choose “Show Package Contents”. 
8. The “.db” file containing the results is located in the AppData/Documents folder. Open 
this file using SQLite Studio  
 
 
 
 
 
 
 
 
 
 
 
 
  
2	
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4.3 SQLiteStudio 
 
In order to access the “.db” files containing the data gathered through the app, SQLiteStudio is a 
great resource. This program is available for free from http://sqlitestudio.pl/ . After opening the 
“.db” files in SQLiteStudio, we can export the data in other formats like .csv for processing in 
data analysis programs like MatLab. 
 
1. Open SQLiteStudio 
2. In the top menu bar, go to Database > Add a database. Select “SQLite 3” for the database 
type. Click the folder icon to browse for the myNuero.db file. You may need to 
copy/paste the “.db” file from within the “.xcappdata” package contents to an outside 
folder to navigate to the file.  
3.  Select the myNeuro.db file and press Ok. 
4. Double click on the database to connect to it or use the connect button in the upper left of 
the window. 
5. Data tables are displayed. Use the “Data” tab to see the contents of the tables. 
6. To export data, right click on a table and select “Export the table”. 
7. Navigate through the export settings changing them as you’d like.  
 
 
These pages have been redacted per request of the author.
